The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of PSMA PET in patients with biochemically recurrent prostate cancer after locoregional definitive therapy.
 
Avanti Gulhane
No Relationships to Disclose
 
Rafee Talukder
No Relationships to Disclose
 
Atreya Dash
Research Funding - Intuitive Surgical (Inst)
Travel, Accommodations, Expenses - Intuitive Surgical
 
William J. Ellis
No Relationships to Disclose
 
George Schade
No Relationships to Disclose
 
Jonathan J. Chen
No Relationships to Disclose
 
Emily Steinberger Weg
No Relationships to Disclose
 
Heather H. Cheng
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I)
Research Funding - Clovis Oncology (Inst); Color Genomics Foundation (Inst); Fred Hutchinson Cancer Research Center (Inst); Janssen (Inst); Medivation/Astellas (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Jessica Hawley
Research Funding - Dendreon; Regeneron
Travel, Accommodations, Expenses - Genzyme
 
John K. Lee
No Relationships to Disclose
 
Robert B. Montgomery
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Beigene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst)
 
Peter S. Nelson
No Relationships to Disclose
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Resverlogix; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)
 
Todd Yezefski
Consulting or Advisory Role - Dendreon
 
Evan Y. Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology; Exelixis; Janssen; Merck
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Dendreon
Research Funding - GenomeDx (Inst); Genomic Health (Inst); Magforce (Inst); MDxHealth (Inst)
 
Delphine L. Chen
No Relationships to Disclose